CaptBeer, yes, I remember.

I just hope they entertain our questions as I'm trying to emphasize a sense of urgency to make something happen and they should embrace their shareholders intelligence and use it to their advantage.

I have encouraged them to review the iHub message board as many of the posters on this board (much smarter than I) can provide Amarin with research and insight.

Thank you all for your questions. I have been able to craft and submit 4 questions to Lisa and KM for their consideration. (Could have presented many more). I focused on Shareholder Equity Growth, EU/UK profitability, New Product Development, and U.S. Strategic Plan - generics and geographic expansion via partnership.

I'll post the questions once I receive feedback from Amarin.

Regards,
Rick

Pharmacydude, thank you.

Thanks.

Yikes! Thanks, I think.

NS, thanks for your questions.

Birdbrain Ideas, thanks for the questions.

jasbg, thank you for your questions.

I plan to weave a question around M&A activity, which could maybe provide insight regarding your #1.

I'm really uncomfortable referencing Dr. Denner in any of these questions.

DTG - thank you for these suggestions.

If folks would like to post questions, I'll coordinate.

iHub Retail Investor Questions for Q1 CC

As you know, I've been trying to converse with Amarin on several subjects. I just heard from Amarin on one of my concerns, no retail representation.

Remember when Thero allowed us to submit questions for one of the conference calls. I've shared this with Lisa to ask KM if he would entertain this consideration.

She responded yes to the following scenario:
We (iHub) provide 3-5 questions, I'll format and send to Lisa, they'll pick 1 and respond, hopefully with substance and insight during the Q&A.

I have to provide the 5 questions by tomorrow, COB. We don't have enough time for a survey, I'm not sure of the best approach to question selection. I guess post your questions, and I'll try to select a good representation from different subjects.

Best I can do with short notice.

dukesking - thanks.

Amarin's BOD and Management Team - INEPT

For the past 2 weeks, I've been trying to gain some insight from Amarin's leadership team regarding today's strategic plan for U.S. market.

Exerps from email exchanges beginning with most recent:

Amarin:
Our management team continues to evaluate all options and opportunities to expand the reach of VASCEPA/VAZKEPA across the globe. Regarding the US market, we are focusing heavily on contribution margin/profitability in order to support the growth in other markets globally.

Me:
I was hoping for a bit more insight and substance. It sounds like Amarin is using the current U.S. revenue level to support EU expansion.

1. Does Amarin have current options on the table to expand the reach of Vascepa/Vazkepa for the U.S. market?

Amarin:
Being just two weeks before we report a new quarter and in a quiet period, it’s difficult to respond to your questions. I expect that we will have an update on these items in a couple of weeks when we report.

Me:
Although you are not able to answer my questions at this time due to the "quiet period", I would like answers after earnings call. I don't expect anything to be conveyed during the call other than paper pushing updates - status quo sugar-coating.

The Shareholders of this company are sick of hearing about Covid and Generics as a crutch to justify poor performance and no deals to expand geographic reach in the U.S. or E.U.

Until or unless the current GIA status quo changes, shareholder equity stock price isn't going anywhere.

It's May, time to announce something.....material.

Stock price in the $2-3s. Really??? The company BOD and leadership is failing - time for changes!

I plan to continue my quest to advocate an M&A strategy to grow shareholder equity quickly rather than GIA and Hope.

Thanks Lizzy

Anyone know how to contact Alex Denner? (email)

Who is responsible for Shareholder Equity Growth?

Resent to Amarin IR (Lisa) and KM.

One of the most concerning observations over the past 2 years, post-patent loss, has been the silence from the current BOD (Mikhail excluded). Nobody really knows what these folks are doing to contribute to shareholder equity growth. As a retail shareholder of Amarin, I cannot think of anything more important than shareholder ROI right now. The BOD appears complacent, not active in any activity with the goal of shareholder equity growth.

One example is Lars Ekman - Chairman of the Board.

Sofinnova Ventures sold their entire position in Amarin; Approx. 1,070,000 shares. As I'm sure you know, Ekman is managing partner at Sofinnova. Why would the top guy, Amarin's Chairman of the Board, completely sell out his position in the company. This doesn't give anyone confidence in the BOD team...again. Why sell now in the $3s if you think the company is heading in the right direction?

What about the other BODs? Are they contributing or are they a "rubber stamp"? Most of these folks are legacy members. We need action by the BOD immediately to present all ideas to grow shareholders equity.

I am requesting the immediate removal of Lars Ekman from Amarin's BOD. We don't need him on our BOD. Selling all his Amarin shares with the price at $3- disgusting.

Email sent to Amarin IR (Lisa) this morning:

When you have time, could you provide commentary regarding options and timeframes to grow the U.S. market vs. Amarin losing 30% of the U.S. market over the last 18 months?

Amarin's share price is grossly undervalued and has been for the past 1-2 years. Amarin Leadership and the BOD have been unable to gain traction in the U.S. and EU. Losing market share to generics in the U.S. and GIA slow walk, paper pushing strategy in the EU is resulting in the share price being range bound between $3 - $3.50. You're running out of time.

This is unacceptable to shareholders.

I am requesting Amarin authorize a review of strategic alternatives to maximize shareholder value. As part of this process, evaluate partnerships in the U.S. and EU geos, a sale of the company, as well as a range of alternatives, including separate sales of business units; U.S, EU, ROW. I would like to see Alex Denner included in this process.

Please let me know leadership's comments regarding my request to maximize shareholder value.

Bidmark,

Hello. I have no knowledge of that.

BOD - No Time to Waste

If Amarin's board is not actively contributing to immediate shareholder equity growth, they should be immediately removed.

We (Amarin shareholders) have been too accepting of this invisible BOD for the past 2 years. iHub and Yahoo message board Amarin shareholders, time to wake up. Join me and email Amarin demanding BOD changes.

The BOD should be operating in emergency mode now before the $500m cash cushion diminishes due to generic revenue erosion and EU start-up costs.

This is the time to revamp the BOD with folks who operate with an immediate sense of urgency to promote shareholder equity growth by including the evaluation of M&A options for a global partnership or merger with big pharma.

BOD Accountability

I can't think of a more important time than now for every BOD member to be held accountable by Amarin shareholders. If they're not contributing to shareholder equity growth, if they are not presenting (or not capable of articulating) ideas for immediate growth, they need to be voted out or pressured to resign.

This BOD works for us, the shareholders (owners) of Amarin.

They're too complacent, that's the way I feel about it.

Where is the creative thinking?
Where is the immediate sense of urgency?

For the past 2 years, too many board members appear silent, and this is not the time to be silent. Speak up. MAKE SOMETHING HAPPEN....

I'm calling on iHub and Yahoo message boards to join me and blitz Amarin IR and KM demanding BOD accountability and replace any complacent, do-nothing BOD members immediately.

Good morning, everyone.

As I mentioned Friday, shareholders really have no idea what this BOD group is doing to promote shareholder equity growth. As a retail shareholder of Amarin, I cannot think of anything more important than shareholder ROI right now. The BOD appears complacent, with no desire to promote ideas other than enjoy the $500m cash cushion while they slow walk and paper push their way around Europe. This "rubber stamp" BOD has to go now.

I have emailed both Lisa D. KM, and Sofinnova requesting the immediate removal of LARS EKMAN as Amarin's COB.

Sofinnova Ventures, led by Ekman has sold their entire position in Amarin; approx. 1,070,000 shares. Why would the top guy, Amarin's Chairman of the Board, completely sell out his position in the company? This doesn't give anyone confidence in the BOD. Why sell now in the $3s if you think the company is heading in the right direction?

These optics are horrendous.

Every Amarin shareholder might want to email Amarin demanding Ekman's immediate removal. We need to look at all legacy BOD members to understand what, (if anything) they are contributing to promote Amarin shareholder growth. Address this like a performance evaluation. Do nothing; you're going to be identified publicly as someone to be removed from the BOD. NO MORE FREE LUNCHES for this clown car.

DAR53, Thank you. I'd like to see other members of this board email Lisa D, KM, and Lars Ekman (IR@sofinnova.com) and share our disgust with what appears to be a "do nothing" BOD.

I cannot fathom how Amarin's COB can sell out of his (Sofinnova's) Amarin position with the stock at $3.

We (shareholders) have been too accepting of this lame BOD for the past 2 years. Now is the time we rally and speak up for change - let them hear us!!!

Regards.

CBB, I agree with you. I suggest every shareholder on this board send an email to Amarin IR requesting the immediate removal of Lars Ekman, Chairman of the Board. The more shareholders denounce this BOD, the better... We collectively need to start voicing our displeasure with board members publicly.

One of the most concerning observations over the past 2 years, post-patent loss, has been the silence from the current BOD (KM excluded). Nobody really knows what these folks are doing to contribute to shareholder equity growth. As a shareholder of Amarin, I cannot think of anything more important than shareholder ROI right now. The BOD appears complacent, not active in any activity with the goal of shareholder equity growth.

One example is Lars Ekman - Chairman of the Board.

It has recently been brought to my attention that Sofinnova Ventures has now sold their entire position in Amarin; Approx. 1,070,000 shares. (Please, correct me if I'm wrong). Ekman is managing partner at Sofinnova. Why would the top guy, Amarin's Chairman of the Board, completely sell out his position in the company? This doesn't give anyone confidence in the BOD team...again. Why sell now in the $3s if you think the company is heading in the right direction?

What about the other BODs? Are they contributing or are they a "rubber stamp"? Most of these folks are legacy members. We need action by the BOD immediately to present all ideas to grow shareholders equity.

I requested the immediate removal of Lars Ekman from Amarin's BOD. We don't need him on our BOD. Selling all his Amarin shares with the price at $3s - disgusting.